Breaking Lane Johnson Hints at 2024 Season Being His Last Darline Graham Enters South Carolina Senate Primary Amidst Experience Questions WNBA Commissioner Addresses Transgender Athlete Participation in League Memo Climate Change Fuels Rise of ‘Mega-Wildfires’ Globally Drones Observed Over German Military Base Amid Airport Discovery Concerns

Saturday August 8, 2026

Reporter

Jaguar Health, Inc.

6Articles Published

5Communities Covered

Published Articles

Press Release

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health’s Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)

Jun 30

Press Release

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

Jun 25

Press Release

Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Jun 23

Press Release

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program

Jun 22

Press Release

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company’s Crofelemer Development Program for Rare Intestinal Failure Diseases

Jun 12

Press Release

Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders

Jun 8